New Cousteau-Linked...
Health Care: Drugs
Achillion Pharmaceuticals Inc. (ACHN: NASDAQ)
$6.95 0.06 | 0.87%
06/04/12 - 02:38 PM ET
Company Cash Flow
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -44.21M | -25.48M | -25.93M | -28.15M |
| Operating Gains/Losses | -111.00K | 6.00K | 0.00 | 4.00K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 143.00K | -181.00K | -65.00K | 136.00K |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 2.12M | 395.00K | -267.00K | 461.00K |
| (Decrease) Increase In Other Current Liabilities | 1.95M | -537.00K | 338.00K | -618.00K |
| (Increase) Decrease In Other Working Capital | 0.00 | 0.00 | 0.00 | -81.00K |
| Other Non-Cash Items | 3.00M | 2.32M | 2.01M | 2.34M |
| Net Cash From Continuing Operations | -35.56M | -23.89M | -22.31M | -24.91M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -35.56M | -23.89M | -22.31M | -24.91M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 9.55M | 31.40M | 38.46M |
| Purchases of Property, Plant & Equipment | -732.00K | -169.00K | -42.00K | -77.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | -80.28M | -39.70M | -7.34M | -40.24M |
| Other Cash from Investing Activities | 0.00 | 0.00 | 53.00K | 52.00K |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -35.24M | -30.32M | 24.07M | -1.80M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 5.00M |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 61.52M | 72.74M | 108.00K | 29.23M |
| Repayment of Long-Term Debt | -546.00K | -2.87M | -3.21M | -5.43M |
| Repurchase of Capital Stock | 146.00K | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 420.00K | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 61.54M | 69.87M | -3.10M | 28.80M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -9.26M | 15.66M | -1.35M | 2.09M |
Portfolios with ACHN
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- UserThe cash burners
- ContributorStocks Under-$10 Moving Hig...
- Contributor10 Hep C Stocks on Wall Str...
- Contributor10 Health-Care Stocks Outpe...
- ContributorHep C Drug Stocks in the Sp...
- UserStocks Under $5
- UserLegal Tender II
- UserTop Picks Under $5 for 2011...
- ContributorTop Stock Picks Under $5 fo...
Latest ACHN Headlines from TheStreet
- Grading Hep C Stocks Exiting EASL Confab 04.23.12 | 09:04 am
- Achillion Stock Gaps Down On Today's Open (ACHN) 04.19.12 | 08:04 am
- For Biotech, 'Fail' is Making a Big Comeback 03.12.12 | 08:03 am
- 8 Stocks Rising on Monster Volume 02.17.12 | 02:02 pm
- Hedge Funds Catch Hep C Fever 02.15.12 | 10:02 am
- Biotech Stock Mailbag: Vical, Hep C Drugs 01.27.12 | 07:01 am
- BioLineRx: Tuesday's Hot Hep C Drug Stock 01.24.12 | 11:01 am
- Idenix Pharma Buyout Likely: Survey 01.20.12 | 03:01 pm
- Biotech Stock Mailbag: Celldex, Hep C Bubble, Al Mann Anger 01.20.12 | 05:01 am
- 4 Companies That Are Bleeding Cash 01.13.12 | 07:01 am
Press Releases for ACHN
- Emerald Holds Annual Groundhog Day Investment Forum - Business Wire 02.06.12 | 08:02 am
Partner Headlines for ACHN
- Achillion Announces 94 - 100% Complete EVR From Phase 2 Trial With ACH-1625 Based Regimen in Hepatitis C - Benzinga 04.21.12 | 04:04 pm
- UPDATE: Bank of America Raises Actuant's PT - Benzinga 03.08.12 | 01:03 pm
- Gilead's Electron Data Brings Some Reality Back To The Hep C Market - Seeking Alpha 02.17.12 | 09:02 am
- 10 Biotech Stocks With 100% Upside In 2012: Part One - Seeking Alpha 02.09.12 | 10:02 am
- Company News for January 25, 2012 - Corporate Summary - Zacks 01.25.12 | 10:01 am
- Afternoon Movers; Negative Euro News - Benzinga 01.24.12 | 04:01 pm
- Benzinga's M&A Chatter for Friday January 20, 2012 - Benzinga 01.20.12 | 06:01 pm
- End-of-Day Market Summary for January 20, 2012 - Benzinga 01.20.12 | 04:01 pm
- Afternoon Movers; Markets Moved Sideways - Benzinga 01.20.12 | 04:01 pm
- 10 Biotech Stocks With Strong Corporate Governance - Seeking Alpha 01.18.12 | 09:01 am
